Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism

British Journal of Haematology

Volumn 154, Issue 2, 2011, Pages 241-247

  Bergrem, Astrid ^a,b   Dahm, Anders Erik Astrup ^a   Jacobsen, Anne Flem ^a   Mowinckel, Marie Christine ^a   Sandvik, Leiv ^a,b   Sandset, Per Morten ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Activated protein C resistance; F5 rs6025 polymorphism (factor V Leiden); Pregnancy; Venous thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTEIN C; PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD EXAMINATION; CALIBRATED AUTOMATED THROMBOGRAPHY; CALIBRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PATIENT SELECTION; PHENOTYPE; POPULATION BASED CASE CONTROL STUDY; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADULT; CASE-CONTROL STUDIES; FACTOR V; FEMALE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROTEIN C; RISK FACTORS; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 79959814150     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08712.x     Document Type: Article

References (32)

1. Aboud, M.R. & Ma, D.D. (2001) Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance. Clinical and Laboratory Haematology, 23, 411-416.
2. Bergrem, A., Jacobsen, E.M., Skjeldestad, F.E., Jacobsen, A.F., Skogstad, M. & Sandset, P.M. (2010) The association of antiphospholipid antibodies with pregnancy-related first time venous thrombosis--a population-based case-control study. Thrombosis Research, 125, e222-e227.
3. Bertina, R.M., Koeleman, B.P., Koster, T., Rosendaal, F.R., Dirven, R.J., de Ronde, H., van der Velden, P.A. & Reitsma, P.H. (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 369, 64-67.
4. Besser, M., Baglin, C., Luddington, R., Van Hylckama, V.A. & Baglin, T. (2008) High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. Journal of Thrombosis and Haemostasis, 6, 1720-1725.
5. Castaman, G., Tosetto, A., Simioni, M., Ruggeri, M., Madeo, D. & Rodeghiero, F. (2001) Phenotypic APC resistance in carriers of the A20210 prothrombin mutation is associated with an increased risk of venous thrombosis. Thrombosis and Haemostasis, 86, 804-808.
6. Castoldi, E. & Rosing, J. (2011) Thrombin generation tests. Thrombosis Research, 127(Suppl. 3), S21-S25.
7. Chan, W.P., Lee, C.K., Kwong, Y.L., Lam, C.K. & Liang, R. (1998) A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood, 91, 1135-1139.
8. Dahlback, B. & Villoutreix, B.O. (2005) Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 1311-1320.
9. Dahm, A., van Hylckama, V.A., Bendz, B., Rosendaal, F., Bertina, R.M. & Sandset, P.M. (2003) Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood, 101, 4387-4392.
10. Hackeng, T.M., Sere, K.M., Tans, G. & Rosing, J. (2006) Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 103, 3106-3111.
11. Haim, N., Lanir, N., Hoffman, R., Haim, A., Tsalik, M. & Brenner, B. (2001) Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. American Journal of Medicine, 110, 91-96.
12. Heinemann, L.A., Assmann, A., Spannagl, M., Schramm, W., Dick, A., Kluft, C. & de Maat, M.P. (1998) Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. Contraception, 58, 321-322.
13. Hemker, H.C., Giesen, P., Giesen, R., Regnault, V., de Smedt, E., Wagenvoord, R., Lecompte, T. & Beguin, S. (2003) Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiology of Haemostasis and Thrombosis, 33, 4-15.
14. Hillarp, A., Dahlback, B. & Zoller, B. (1995) Activated protein C resistance: from phenotype to genotype and clinical practice. Blood Reviews, 9, 201-212.
15. Hoffman, M., Monroe, D.M., Oliver, J.A. & Roberts, H.R. (1995) Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood, 86, 1794-1801.
16. Hoibraaten, E., Mowinckel, M.C., de Ronde, H., Bertina, R.M. & Sandset, P.M. (2001) Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. British Journal of Haematology, 115, 415-420.
17. Jacobsen, A.F., Skjeldestad, F.E. & Sandset, P.M. (2008) Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. Journal of Thrombosis and Haemostasis, 6, 905-912.
18. de Laat, B., Eckmann, C.M., van Schagen, M., Meijer, A.B., Mertens, K. & van Mourik, J.A. (2008) Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. Blood Coagulation and Fibrinolysis, 19, 757-764.
19. Norstrom, E., Thorelli, E. & Dahlback, B. (2002) Functional characterization of recombinant FV Hong Kong and FV Cambridge. Blood, 100, 524-530.
20. Rees, D.C., Cox, M. & Clegg, J.B. (1995) World distribution of factor V Leiden. Lancet, 346, 1133-1134.
21. Rodeghiero, F. & Tosetto, A. (1999) Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Annals of Internal Medicine, 130, 643-650.
22. Rosing, J. & Tans, G. (1999) Effects of oral contraceptives on hemostasis and thrombosis. American Journal of Obstetrics and Gynecology, 180, S375-S382.
23. Rosing, J., Hemker, H.C. & Tans, G. (1998) Molecular biology and pathophysiology of APC resistance: current insights and clinical implications. Seminars in Thrombosis and Hemostasis, 24, 329-335.
24. Tans, G., van Hylckama, V.A., Thomassen, M.C., Curvers, J., Bertina, R.M., Rosing, J. & Rosendaal, F.R. (2003) Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. British Journal of Haematology, 122, 465-470.
25. Tosetto, A., Missiaglia, E., Gatto, E. & Rodeghiero, F. (1997) The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis. Thrombosis and Haemostasis, 78, 859-863.
26. Tripodi, A., Legnani, C., Chantarangkul, V., Cosmi, B., Palareti, G. & Mannucci, P.M. (2008) High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. Journal of Thrombosis and Haemostasis, 6, 1327-1333.
27. Van Hylckama, V.A., Christiansen, S.C., Luddington, R., Cannegieter, S.C., Rosendaal, F.R. & Baglin, T.P. (2007) Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. British Journal of Haematology, 138, 769-774.
28. de Visser, M.C., Rosendaal, F.R. & Bertina, R.M. (1999) A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood, 93, 1271-1276.
29. de Visser, M.C., van Hylckama, V.A., Tans, G., Rosing, J., Dahm, A.E., Sandset, P.M., Rosendaal, F.R. & Bertina, R.M. (2005) Determinants of the APTT - and the ETP - based APC sensitivity tests. Journal of Thrombosis and Haemostasis, 3, 1488-1494.
30. Walker, M.C., Garner, P.R., Keely, E.J., Rock, G.A. & Reis, M.D. (1997) Changes in activated protein C resistance during normal pregnancy. American Journal of Obstetrics and Gynecology, 177, 162-169.
31. Williamson, D., Brown, K., Luddington, R., Baglin, C. & Baglin, T. (1998) Factor V Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C. Blood, 91, 1140-1144.
32. Zotz, R.B., Gerhardt, A., Kluft, C. & Scharf, R.E. (2005) Venous thromboembolism during pregnancy is not associated with persistent elevated activated protein C (APC) sensitivity ratio based on the endogenous thrombin potential. Thrombosis and Haemostasis, 93, 306-310.